Profound Medical Corp
Open
$9.25
Prev. Close
$9.22
High
$9.25
Low
$9.11
Market Snapshot
$226.8M
-1.41
$16.1M
162
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
emptyResult
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Recently from Cashu
Profound Medical Corp. Innovates BPH Treatment with TULSA-PRO and TULSA-AI Technology
Profound Medical Corp. Leads Innovation in BPH Treatment with TULSA-PRO System Profound Medical Corporation achieves a significant milestone in the treatment of benign prostatic hyperplasia (BPH) with…
Profound Medical Corp. Transforms BPH Treatment with TULSA-PRO and TULSA-AI Integration
Profound Medical Revolutionizes BPH Treatment with TULSA-PRO and TULSA-AI Integration On June 10, 2025, Profound Medical Corp. achieves a significant milestone in urological care by successfully perfo…
Profound Medical Corp. Leads in Minimally Invasive Therapies for Prostate and Uterine Conditions
Profound Medical Corp. Advances in Minimally Invasive Therapies Profound Medical Corp. continues to position itself as a leader in the field of innovative medical devices, with a strong emphasis on mi…
Profound Medical Corp. TULSA Trial Shows Promising Results for Prostate Cancer Treatment
Profound Medical Corp. Advances Prostate Cancer Treatment with TULSA Trial Results Profound Medical Corp. announces promising initial results from its Level 1 CAPTAIN trial, which assesses the efficac…